Graham Temple

868 total citations
17 papers, 721 citations indexed

About

Graham Temple is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Graham Temple has authored 17 papers receiving a total of 721 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Graham Temple's work include Renal cell carcinoma treatment (7 papers), Lung Cancer Treatments and Mutations (6 papers) and HER2/EGFR in Cancer Research (5 papers). Graham Temple is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Lung Cancer Treatments and Mutations (6 papers) and HER2/EGFR in Cancer Research (5 papers). Graham Temple collaborates with scholars based in United Kingdom, Germany and Austria. Graham Temple's co-authors include Johann S. de Bono, Ruth Plummer, Hilary Calvert, P. Andrew Futreal, James Spicer, Martina Uttenreuther‐Fischer, Laura Vidal, Heather Shaw, Mehdi Shahidi and Susan Bell and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Graham Temple

17 papers receiving 706 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Graham Temple United Kingdom	12	441	431	288	132	84	17	721
Adriano Gravina Italy	16	591 1.3×	317 0.7×	193 0.7×	148 1.1×	171 2.0×	53	958
Brooke Esteves United States	11	312 0.7×	283 0.7×	312 1.1×	185 1.4×	201 2.4×	31	662
Johann Raats South Africa	9	367 0.8×	280 0.6×	188 0.7×	54 0.4×	83 1.0×	15	569
F Penault–Llorca France	11	459 1.0×	172 0.4×	194 0.7×	36 0.3×	212 2.5×	35	722
Damiano Italy	6	634 1.4×	446 1.0×	346 1.2×	22 0.2×	72 0.9×	11	885
Mareyuki Endoh Japan	18	187 0.4×	195 0.5×	306 1.1×	28 0.2×	158 1.9×	33	786
Bianco Ar Italy	5	615 1.4×	432 1.0×	329 1.1×	23 0.2×	66 0.8×	7	844
P.N. Munster United States	12	336 0.8×	119 0.3×	307 1.1×	22 0.2×	79 0.9×	18	584
Robert C. Whorf United States	10	418 0.9×	477 1.1×	346 1.2×	51 0.4×	200 2.4×	20	790
Giacomo Pelizzari Italy	15	394 0.9×	271 0.6×	146 0.5×	27 0.2×	158 1.9×	50	623

Countries citing papers authored by Graham Temple

Since Specialization

Citations

This map shows the geographic impact of Graham Temple's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graham Temple with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graham Temple more than expected).

Fields of papers citing papers by Graham Temple

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Graham Temple. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graham Temple. The network helps show where Graham Temple may publish in the future.

Co-authorship network of co-authors of Graham Temple

This figure shows the co-authorship network connecting the top 25 collaborators of Graham Temple. A scholar is included among the top collaborators of Graham Temple based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Graham Temple. Graham Temple is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Eisen, Tim, Yaroslav Shparyk, Nicholas MacLeod, et al.. (2015). A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer. 113(8). 1140–1147. 32 indexed citations

Taylor, N. Jane, Gerhardt Attard, Simon Pacey, et al.. (2015). Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors. The Oncologist. 20(4). 368–369. 5 indexed citations

Ring, Alistair, Duncan Wheatley, Helen Hatcher, et al.. (2014). Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research. 21(12). 2737–2744. 16 indexed citations

Molife, L. Rhoda, Aurelius Omlin, Robert J. Jones, et al.. (2014). Randomized Phase II Trial of Nintedanib, Afatinib and Sequential Combination in Castration-Resistant Prostate Cancer. Future Oncology. 10(2). 219–231. 30 indexed citations

Eisen, Tim, Yaroslav Shparyk, Nicholas MacLeod, et al.. (2013). Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational New Drugs. 31(5). 1283–1293. 48 indexed citations

Eisen, Tim, Yaroslav Shparyk, Robert H. Jones, et al.. (2013). Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients.. Journal of Clinical Oncology. 31(15_suppl). 4506–4506. 21 indexed citations

Eisen, Tim, Yaroslav Shparyk, Nicholas MacLeod, et al.. (2012). Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study.. Journal of Clinical Oncology. 30(15_suppl). e15037–e15037. 1 indexed citations

Ledermann, Jonathan A., Allan Hackshaw, Gordon C. Jayson, et al.. (2011). Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology. 29(28). 3798–3804. 164 indexed citations

Yap, Timothy A., Laura Vidal, Jan Adam, et al.. (2010). Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 28(25). 3965–3972. 295 indexed citations

10.

Ledermann, Jonathan A., Gordon Rustin, A. Hackshaw, et al.. (2009). A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). Journal of Clinical Oncology. 27(15_suppl). 5501–5501. 32 indexed citations

11.

Plummer, Ruth, Rebecca M. Perrett, James Spicer, et al.. (2007). 703 POSTER A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor. European Journal of Cancer Supplements. 5(4). 108–108. 5 indexed citations

12.

Spicer, James, Hilary Calvert, Laura Vidal, et al.. (2007). D7-02: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR. Journal of Thoracic Oncology. 2(8). S410–S410. 14 indexed citations

13.

Padhani, Anwar R., N. Jane Taylor, James A. d’Arcy, et al.. (2006). Dynamic MRI evaluation of the triple receptor tyrosine kinase inhibitor BIBF 1120 in patients with advanced solid tumours. 5 indexed citations

14.

Taylor, N. Jane, Gerhardt Attard, Paul Nathan, et al.. (2006). A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Journal of Clinical Oncology. 24(18_suppl). 3015–3015. 17 indexed citations

15.

Shaw, Heather, Ruth Plummer, Rebecca M. Perrett, et al.. (2006). A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours. Journal of Clinical Oncology. 24(18_suppl). 3027–3027. 19 indexed citations

16.

Plummer, Ruth, Laura Vidal, H. M. Shaw, et al.. (2006). 573 POSTER Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumors with mutated EGFR. European Journal of Cancer Supplements. 4(12). 173–174. 4 indexed citations

17.

Attard, Gerhardt, Paul Nathan, Johann S. de Bono, et al.. (2005). A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. Journal of Clinical Oncology. 23(16_suppl). 3054–3054. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact